Using 2D and 3D preclinical models with distinct genetic backgrounds, we demonstrate the potential utility of HDAC inhibitors for the chemoprevention of HDGC and treatment of sporadic E-cadherin-deficient cancers. The gene discussed is CDH1; the disease is cancer.